🩸 Can ctDNA capture response before surgery in MIBC?
https://oncodaily.com/oncolibrary/immune-oncology/keynote-b15-ctdna
Exploratory KEYNOTE-B15/EV-304 analysis:
ctDNA clearance: 82.1% with EV + pembrolizumab vs 66.7% with gemcitabine–cisplatin.
Clearance was associated with better EFS.
#ESMO2026 #OncoDaily #ESMO26 #KEYNOTEB15
120 浏览 · 1 赞 · 1 转发 · 0 回复
ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.org- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
https://esmocongress.esmo.org来源：OncoDaily IO · x.com